KMT2D mutation + TMB-H
|
NSCLC
|
KMT2D mutation + TMB-H
|
NSCLC
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
KMT2D mutation + TMB-H
|
NSCLC
|
KMT2D mutation + TMB-H
|
NSCLC
|
PD1 inhibitor + CTLA4 inhibitor Sensitive: B - Late Trials
|
PD1 inhibitor + CTLA4 inhibitor Sensitive: B - Late Trials
|
KMT2D mutation + TMB-H
|
CRC
|
KMT2D mutation + TMB-H
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|